DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Johnson - 1 Raj Joshi - 1 It's - 1 EY - 1 it's - 1 Colette Kress - 1 Roche's Genentech - 1
Top related locs:
Arda Americas Ural NVIDIA Clara
Top related orgs:
Nvidia - 1 Johnson - 1 GE Healthcare - 1 Companies - 1 NVIDIA - 1 NVIDIA BioNeMo - 1

Search resuls for: "Roche's Genentech"


4 mentions found


☆ Nvidia's AI ambitions in medicine and health care are becoming clear
  + stars: | 2024-03-24 | by ( Michelle Castillo | ) www.cnbc.com   time to read: +3 min
Last week, Nvidia announced deals with Johnson & Johnson for use of generative AI in surgery, and with GE Healthcare to improve medical imaging. "Health care, whether it's biotechnology, chemicals, or drug discovery is a very powerful area." About 41 percent of biotech CEOs surveyed by EY in late 2023 said they were looking at "concrete" ways generative AI could be used for their companies. "This is very high for my experience, having been 30 years in this industry," Ural said. It also partnered in 2021 with Schrödinger for drug discovery.
Persons: Johnson, Raj Joshi, It's, EY, it's, Colette Kress, Roche's Genentech Organizations: Nvidia, Johnson, GE Healthcare, Companies, NVIDIA, NVIDIA BioNeMo Locations: Arda, Americas, Ural, NVIDIA Clara
☆ Bristol Myers CEO Caforio steps down
  + stars: | 2023-04-26 | by ( ) www.reuters.com   time to read: +1 min
[1/2] A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File PhotoCompanies Bristol-Myers Squibb Co FollowApril 26 (Reuters) - Bristol Myers Squibb Co (BMY.N) said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Outgoing CEO Giovanni will continue as executive chairman of the company's board. Bristol Myers is due to report first-quarter financial results on Thursday. Bristol Myers shares rose 0.39% to $68.29 in after-hours trading.
☆ Genentech sues Biogen for royalties on blockbuster MS drug
  + stars: | 2023-03-01 | by ( Blake Brittain | Thomson Reuters | Blake Brittain Reports On Intellectual Property Law | ) www.reuters.com   time to read: +2 min
March 1 (Reuters) - Roche's Genentech Inc (ROGING.UL) sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri. Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later. According to Genentech, Biogen has refused to pay royalties on any Tysabri sales since the patents expired more than four years ago. It said Biogen owes royalties for "most or all" of the Tysabri sold in "2019 and beyond," which it said was made with the patented technology before the patents expired. The case is Genentech Inc v. Biogen MA Inc, U.S. District Court for the Northern District of California, No.
☆ Brazilian soccer legend Pelé died of colon cancer. Here are the cutting-edge clinical trials trying to find new treatments for the disease.
  + stars: | 2022-12-30 | by ( Sarah Braner | ) www.businessinsider.com   time to read: +4 min
The Brazilian soccer legend Pelé died of colon cancer Thursday at 82. Colon cancer is the third most common cancer, affecting almost 2 million people each year. Colorectal cancer is the third most common cancer, according to the World Cancer Research Fund International. Pelé isn't the only celebrity to have died of colon cancer in recent years — the Black Panther star Chadwick Boseman died of the disease in 2020 at the age of 43. Here are the cutting-edge phase-three clinical trials for colon cancer, in order of how recently they began.
0 next >>
Total: 4